In addition to ANX-530, ANX-514, ADVENTRX holds rights to a number of other compounds that the Company is evaluating for future preclinical and/or clinical development. These include:

• ANX-211, an anti-viral nasal spray. A patent-protected aqueous formulation of chitosan and other ingredients designed to protect users from bacterial and viral infections, including common cold, influenza, and other infections of the upper respiratory tract. ANX-211 has been shown to prevent infection of human cell lines by human influenza B virus, human rhinovirus and adenovirus, major causes of the flu and common cold;